search
Back to results

Sympathetic Mapping/ Ablation of Renal Nerves Trial (SMART)

Primary Purpose

Hypertension

Status
Active
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator
Sponsored by
SyMap Medical (Suzhou), Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male and non-pregnant female subjects, 18≤age≤65
  2. Essential hypertension
  3. Office systolic blood pressure ≥150mmHg and ≤180mmHg; and resting heart rate ≥70 bpm without taking beta blocker(Resting heart rate does not taken into account if beta blocker is taken)
  4. Average 24-hour ABPM systolic blood pressure ≥130mmHg, or ABPM systolic blood pressure during daytime ≥ 135mmHg, or ABPM systolic blood pressure during nighttime ≥ 120mmHg
  5. History of hypertension is longer than 6 months
  6. Patient with poor blood pressure control after 6 months of antihypertensive drug therapy, understands the purpose of this study, and is willing to participate and sign the Informed Consent; then the patient receives standard antihypertensive drug treatment (at least two drugs) for at least 28 days, drug compliance ≥80%, office systolic blood pressure ≥150 mmHg and ≤180 mmHg.
  7. Patient is compliant and willing to complete clinical follow-up.

Exclusion Criteria:

  1. Renal artery anatomy is unqualified including: (1) diameter <4mm or treatable length <25mm, (2) multiple renal arteries and the main renal artery supplies a fraction of the blood flow less than 75%, (3) renal artery stenosis >50% or any renal artery aneurysms on either side, (4) history of renal artery PTA, including balloon angioplasty and stenting.
  2. eGFR <45mL/min/1.73m2 (MDRD formula)
  3. Hospitalized within one year due to hypertensive crisis
  4. Average 24-hour systolic blood pressure <130mmHg and ABPM systolic blood pressure during daytime ≤ 135mmHg, and ABMP systolic blood pressure during nighttime ≤ 120mmHg
  5. Pulse pressure >80mmHg
  6. During running in period, using antihypertensive drugs other than standardized antihypertensive drugs
  7. Participated other clinical trials including both drug and medical device studies within 3 months from current study
  8. Female with pregnant or lactating, or having plans for pregnancy within 1 year
  9. Patient with sleep apnea who needs chronic oxygen-breathing or mechanical ventilation support (for example, tracheostomy)
  10. Patients previously or currently suffering from following diseases:

(1) essential pulmonary arterial hypertension, (2) type I diabetes, (3) patients with severe cardiac valvular stenosis who have contradictions and cannot rolerant to significantly reduce blood pressure, (4) within half year, patients had myocardial infraction, unstable angina, syncope or cerebrovascular accidents, (5) history of primary aldosteronism, pheochromocytoma, aorta stenosis, hyperthyroidism or hyperparathyreosis, (6) any disease conditions interfering the measurement of blood pressure (for instance, severe peripheral artery diseases, abdominal artery aneurysm, hemorrhagic disorders such as thrombocytopenia, hemophilia and severe anemia), (7) plans to have surgery or cardiovascular interventions within 6 months, (8) alcohol abuse or unknown drug dependence history, (9) neuroticisms such as depression or anxiety disorders, (10) non-compliant patients who are unable to follow the study protocol per physician's requests.

11. Any contradictions to conduct renal artery stimulation and ablation

Sites / Locations

  • Peking University First Hospital
  • Peking University People's Hospital
  • The Second Afflicted Hospital of Chongqing Medical University
  • Shenzhen People's Hospital
  • Norman Bethune International Peace Hospital
  • Hebei General Hospital
  • Daqing Oilfield General Hospital
  • Renmin Hospital of Wuhan University
  • Nanjing First Hospital
  • Jiangsu Province Hospital
  • The Affiliated Hospital of Xuzhou Medical University
  • Shanghai Zhongshan Hospital, Fudan University
  • Taiyuan Central Hospital
  • West China Hospital, Sichuan University
  • Tianjin First Center Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

Renal Sympathetic Denervation

Masked Procedure

Arm Description

Percutaneous renal denervation using the SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator.

Percutaneous renal artery angiography

Outcomes

Primary Outcome Measures

The control rate of office systolic blood pressure ( SBP<140mmHg)
The control rate of office systolic blood pressure ( SBP<140mmHg) at 6 months after the treatment
Change in the composite index of antihypertensive drugs to reach control of office systolic blood pressure (<140mmHg)
Change in the composite index of antihypertensive drugs to reach control of office systolic blood pressure (<140mmHg) at 6 months after the treatment

Secondary Outcome Measures

Reduction in average 24-hour Ambulatory Blood Pressure Monitoring (ABPM) systolic blood pressure
Postoperative reduction in 24-hour ABPM in systolic, diastolic and mean arterial blood pressure
Reduction in office blood pressure
Change in composite index of antihypertensive drugs
Success rate of the renal interventional therapy procedure
the renal denervation catheter can be engaged to the correct position in renal artery, successfully performed renal nerve ablation procedure and has no related complications such as renal arterial perforation
Success rate of clinical treatment
based on succeed performance of renal interventional therapy procedure , there are no the procedure-related SAE, such as acute infection and renal dysfunction
All-cause death
Severe renal dysfunction
eGFR<15mL/min/m2 or renal function replacement therapy needed
Rate of renal artery stenosis assessed by CT angiography
(stenosis > 70% )
AEs, SAEs, and severe cardio-cerebrovascular events
Reduction in 24-hour ABPM in systolic and diastolic arterial blood pressure

Full Information

First Posted
May 3, 2016
Last Updated
July 31, 2023
Sponsor
SyMap Medical (Suzhou), Ltd.
Collaborators
Tigermed Consulting Co., Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT02761811
Brief Title
Sympathetic Mapping/ Ablation of Renal Nerves Trial
Acronym
SMART
Official Title
A Prospective, Multicenter, Single Blind, Randomized and Sham Controlled Trial of Renal Sympathetic Denervation Using SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator for the Treatment of Hypertension (SMART Trial)
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
June 30, 2016 (undefined)
Primary Completion Date
August 25, 2022 (Actual)
Study Completion Date
December 31, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
SyMap Medical (Suzhou), Ltd.
Collaborators
Tigermed Consulting Co., Ltd

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To evaluate the safety and efficacy of targeted renal sympathetic denervation using SyMapCath I® and SYMPIONEER S1® Stimulator/ Generator in patients with essential hypertension for at least 6 months of the disease history and pharmacotherapy, however, their blood pressure still cannot be controlled, then after standardized antihypertensive drug therapy (at least two drugs) for at least 28 days, office systolic blood pressure is still ≥ 150mmHg, ≤180mmHg.
Detailed Description
This is a prospective, multicenter, single blind, randomized and sham controlled trial, in which patients are diagnosed with essential hypertension with at least six months of the disease history and pharmacotherapy however their blood pressure still cannot be controlled. The patients will be informed, consent and get into a screening process. During the screening period patients will receive a standardized antihypertensive drug treatment for at least 28 days and office systolic blood pressure is still ≥ 150mmHg, ≤180mmHg, and meet the inclusion and exclusion criteria. These patients will conduct renal artery angiography and be allocated to either renal sympathetic nerve denervation group or renal artery angiography group by a randomizing system in a 1:1 ratio (220 patients, 110 pairs). Patients with office systolic blood pressure which is not achieved ideal level (<140 mmHg) will titrate doses or classes of antihypertensive drugs according to a predefined standardized medication regimen until their office systolic blood pressure <140 mmHg, whereas in principle patients should follow the drug titration regimen, however, it is allowed to adjust antihypertensive medications per the real-world needs after 12 months. Physicians who perform post-procedure patient management and physicians who perform renal denervation procedures are blinded to each other. Patients will be followed at 7 days after the procedure or at discharge from hospital, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 9 months, 12months, 24months, 36 months, 48 months and 60 months for blood pressure measurements and antihypertensive medications. Urine samples will be collected for drug tests (LC-MS/MS) to determine drug compliance of a patient by an independent laboratory. Data collecting/management/statistical analysis and laboratory tests will be done by independent, qualified organizations. Independent DSMB/CEC are formed and responsible for assessments of protocol deviations and natures of SAEs.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
220 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Renal Sympathetic Denervation
Arm Type
Experimental
Arm Description
Percutaneous renal denervation using the SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator.
Arm Title
Masked Procedure
Arm Type
Sham Comparator
Arm Description
Percutaneous renal artery angiography
Intervention Type
Device
Intervention Name(s)
SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator
Intervention Description
Radiofrequency ablation of renal arterial sympathetic nerves
Primary Outcome Measure Information:
Title
The control rate of office systolic blood pressure ( SBP<140mmHg)
Description
The control rate of office systolic blood pressure ( SBP<140mmHg) at 6 months after the treatment
Time Frame
6 months after the treatment
Title
Change in the composite index of antihypertensive drugs to reach control of office systolic blood pressure (<140mmHg)
Description
Change in the composite index of antihypertensive drugs to reach control of office systolic blood pressure (<140mmHg) at 6 months after the treatment
Time Frame
6 months after the treatments
Secondary Outcome Measure Information:
Title
Reduction in average 24-hour Ambulatory Blood Pressure Monitoring (ABPM) systolic blood pressure
Time Frame
6 months
Title
Postoperative reduction in 24-hour ABPM in systolic, diastolic and mean arterial blood pressure
Time Frame
discharge day or 7 days after procedure
Title
Reduction in office blood pressure
Time Frame
1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 12 months, 24months, 36 months, 48 months and 60 months
Title
Change in composite index of antihypertensive drugs
Time Frame
1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 12 months, 24months, 36 months, 48 months and 60 months
Title
Success rate of the renal interventional therapy procedure
Description
the renal denervation catheter can be engaged to the correct position in renal artery, successfully performed renal nerve ablation procedure and has no related complications such as renal arterial perforation
Time Frame
during the procedure
Title
Success rate of clinical treatment
Description
based on succeed performance of renal interventional therapy procedure , there are no the procedure-related SAE, such as acute infection and renal dysfunction
Time Frame
7 days after the procedure or at the time the patient is discharged from hospital
Title
All-cause death
Time Frame
1 month, 3 months, 6 months, 9 months, 12 months, 24months, 36 months, 48 months and 60 months
Title
Severe renal dysfunction
Description
eGFR<15mL/min/m2 or renal function replacement therapy needed
Time Frame
6 months, 24months, 36 months, 48 months and 60 months
Title
Rate of renal artery stenosis assessed by CT angiography
Description
(stenosis > 70% )
Time Frame
6 months, 24months, 36 months, 48 months and 60 months
Title
AEs, SAEs, and severe cardio-cerebrovascular events
Time Frame
1 month, 3 months, 6 months, 9 months, 12months, 24months, 36 months, 48 months and 60 months
Title
Reduction in 24-hour ABPM in systolic and diastolic arterial blood pressure
Time Frame
24, 36, 48, 60 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and non-pregnant female subjects, 18≤age≤65 Essential hypertension Office systolic blood pressure ≥150mmHg and ≤180mmHg; and resting heart rate ≥70 bpm without taking beta blocker(Resting heart rate does not taken into account if beta blocker is taken) Average 24-hour ABPM systolic blood pressure ≥130mmHg, or ABPM systolic blood pressure during daytime ≥ 135mmHg, or ABPM systolic blood pressure during nighttime ≥ 120mmHg History of hypertension is longer than 6 months Patient with poor blood pressure control after 6 months of antihypertensive drug therapy, understands the purpose of this study, and is willing to participate and sign the Informed Consent; then the patient receives standard antihypertensive drug treatment (at least two drugs) for at least 28 days, drug compliance ≥80%, office systolic blood pressure ≥150 mmHg and ≤180 mmHg. Patient is compliant and willing to complete clinical follow-up. Exclusion Criteria: Renal artery anatomy is unqualified including: (1) diameter <4mm or treatable length <25mm, (2) multiple renal arteries and the main renal artery supplies a fraction of the blood flow less than 75%, (3) renal artery stenosis >50% or any renal artery aneurysms on either side, (4) history of renal artery PTA, including balloon angioplasty and stenting. eGFR <45mL/min/1.73m2 (MDRD formula) Hospitalized within one year due to hypertensive crisis Average 24-hour systolic blood pressure <130mmHg and ABPM systolic blood pressure during daytime ≤ 135mmHg, and ABMP systolic blood pressure during nighttime ≤ 120mmHg Pulse pressure >80mmHg During running in period, using antihypertensive drugs other than standardized antihypertensive drugs Participated other clinical trials including both drug and medical device studies within 3 months from current study Female with pregnant or lactating, or having plans for pregnancy within 1 year Patient with sleep apnea who needs chronic oxygen-breathing or mechanical ventilation support (for example, tracheostomy) Patients previously or currently suffering from following diseases: (1) essential pulmonary arterial hypertension, (2) type I diabetes, (3) patients with severe cardiac valvular stenosis who have contradictions and cannot rolerant to significantly reduce blood pressure, (4) within half year, patients had myocardial infraction, unstable angina, syncope or cerebrovascular accidents, (5) history of primary aldosteronism, pheochromocytoma, aorta stenosis, hyperthyroidism or hyperparathyreosis, (6) any disease conditions interfering the measurement of blood pressure (for instance, severe peripheral artery diseases, abdominal artery aneurysm, hemorrhagic disorders such as thrombocytopenia, hemophilia and severe anemia), (7) plans to have surgery or cardiovascular interventions within 6 months, (8) alcohol abuse or unknown drug dependence history, (9) neuroticisms such as depression or anxiety disorders, (10) non-compliant patients who are unable to follow the study protocol per physician's requests. 11. Any contradictions to conduct renal artery stimulation and ablation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yong HUO, MD
Organizational Affiliation
Peking University First Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Peking University First Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100038
Country
China
Facility Name
Peking University People's Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100044
Country
China
Facility Name
The Second Afflicted Hospital of Chongqing Medical University
City
Chongqing
State/Province
Chongqing
ZIP/Postal Code
400016
Country
China
Facility Name
Shenzhen People's Hospital
City
Shenzhen
State/Province
Guangdong
ZIP/Postal Code
518020
Country
China
Facility Name
Norman Bethune International Peace Hospital
City
Shijiazhuang
State/Province
Hebei
ZIP/Postal Code
050000
Country
China
Facility Name
Hebei General Hospital
City
Shijiazhuang
State/Province
Hebei
ZIP/Postal Code
050057
Country
China
Facility Name
Daqing Oilfield General Hospital
City
Daqing
State/Province
Heilongjiang
ZIP/Postal Code
163458
Country
China
Facility Name
Renmin Hospital of Wuhan University
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430060
Country
China
Facility Name
Nanjing First Hospital
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210000
Country
China
Facility Name
Jiangsu Province Hospital
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210029
Country
China
Facility Name
The Affiliated Hospital of Xuzhou Medical University
City
Xuzhou
State/Province
Jiangsu
ZIP/Postal Code
221004
Country
China
Facility Name
Shanghai Zhongshan Hospital, Fudan University
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200032
Country
China
Facility Name
Taiyuan Central Hospital
City
Taiyuan
State/Province
Shanxi
ZIP/Postal Code
030009
Country
China
Facility Name
West China Hospital, Sichuan University
City
Chengdu
State/Province
Sichuan
ZIP/Postal Code
610041
Country
China
Facility Name
Tianjin First Center Hospital
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300192
Country
China

12. IPD Sharing Statement

Plan to Share IPD
Undecided
IPD Sharing Plan Description
Our decision on whether to share the individual participant data depends on the opinions of the regulatory authorities in China, but so far the regulatory agencies have no clear instructions yet, thus we cannot make a decision at present.
Citations:
PubMed Identifier
36042146
Citation
Wang J, Sun N, Ge J, Jiang H, Yin Y, Chen M, Wang Y, Yao C, Yan X, Sobotka PA, Huo Y. Rationale and Design of Sympathetic Mapping/Ablation of Renal Nerves Trial (SMART) for the Treatment of Hypertension: a Prospective, Multicenter, Single-Blind, Randomized and Sham Procedure-Controlled Study. J Cardiovasc Transl Res. 2023 Apr;16(2):358-370. doi: 10.1007/s12265-022-10307-z. Epub 2022 Aug 30.
Results Reference
derived
PubMed Identifier
34269698
Citation
Wang Y, Wang JW, Wang Y, Yang B, Yinghua Du A, Kong Z, Chen M, Wang J. Monitoring Antihypertensive Medication Adherence by Liquid Chromatography-Tandem Mass Spectrometry: Method Establishment and Clinical Application. J Cardiovasc Pharmacol. 2021 Oct 1;78(4):581-596. doi: 10.1097/FJC.0000000000001105.
Results Reference
derived

Learn more about this trial

Sympathetic Mapping/ Ablation of Renal Nerves Trial

We'll reach out to this number within 24 hrs